Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
about
Prospects for vaccine prevention of meningococcal infectionFine antigenic specificity and cooperative bactericidal activity of monoclonal antibodies directed at the meningococcal vaccine candidate factor h-binding proteinPhase I safety and immunogenicity study of a candidate meningococcal disease vaccine based on Neisseria lactamica outer membrane vesicles.Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat modelUtilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroadsProtection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccineProtection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant ratsEarly appearance of bactericidal antibodies after polysaccharide challenge of toddlers primed with a group C meningococcal conjugate vaccine: what is its role in the maintenance of protection?A meningococcal factor H binding protein mutant that eliminates factor H binding enhances protective antibody responses to vaccinationImmunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.Enhanced bacteremia in human factor H transgenic rats infected by Neisseria meningitidisImmunization strategies for the control of serogroup C meningococcal disease in developed countries.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.A generic mechanism in Neisseria meningitidis for enhanced resistance against bactericidal antibodies.Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.fH-dependent complement evasion by disease-causing meningococcal strains with absent fHbp genes or frameshift mutations.Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infantsEvidence of a functional B-cell immunodeficiency in adults who experience serogroup C meningococcal diseaseRelative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.Neisseria lactamica antigens complexed with a novel cationic adjuvantEx vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.Commentary: Impact of meningococcal group B OMV vaccines, beyond their brief.
P2860
Q24537338-40723023-3703-4B01-9ACC-A8A8BC1A5D04Q30157650-2FF63FD1-C799-4A44-AF4D-1DFDA84B9558Q30227840-894BB7C1-19D8-45A5-BB6D-4E43C1F8D3BEQ33602953-595C2FFF-1417-426C-A460-73CCBFA5D324Q33916408-60EFD513-59E0-4F0C-941B-A9C36EEC3EE0Q33946852-BD90223E-6B89-4A3E-9E8E-D8BD62A0E484Q34480575-610BC418-6EC8-423A-AB04-F1D96D411B6CQ34602010-C0D56768-39E6-4BDE-B75E-E3AB178A46BDQ34975007-EF4E874E-E66D-4022-A5F3-8F0D7270668AQ34993283-08499EA4-8B0D-4DDE-9C52-4BB755A216EAQ35680467-70CCD6B9-7CE8-4946-A7C7-E09595520992Q35689526-926A6A0A-EF69-404A-A6A1-978608A9D312Q36445558-D773A951-700C-4A1B-86D4-15C571990DE9Q36600323-AE27DDEF-DFC2-46A8-B60D-3A30B44670ADQ36699790-CF973421-6A65-4727-8A3B-9070E2B8F522Q37075472-F2213FE9-D9DD-4585-B382-51F4A6001C0DQ37130358-7CE71DCF-24CE-48D7-90A0-FA4BE54AD1CBQ37131083-8E5E7F8F-B653-4191-AC6C-F5ABFA69CA81Q37190952-ECEB9753-C7A1-44CB-B7B0-476AB2B5C58DQ37362174-1BA235E7-4D7D-46A8-BF20-2D23446C7998Q37478314-B6C59F35-84F0-4C25-B603-53CDBDB241DAQ42173007-842A6986-ED28-45BC-8F0B-A31AA932EABDQ46280467-52C5902E-D946-48E5-9335-E8E4E3F75F03
P2860
Naturally acquired passive protective activity against Neisseria meningitidis Group C in the absence of serum bactericidal activity.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2004
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Naturally acquired passive pro ...... f serum bactericidal activity.
@en
Naturally acquired passive pro ...... f serum bactericidal activity.
@nl
type
label
Naturally acquired passive pro ...... f serum bactericidal activity.
@en
Naturally acquired passive pro ...... f serum bactericidal activity.
@nl
prefLabel
Naturally acquired passive pro ...... f serum bactericidal activity.
@en
Naturally acquired passive pro ...... f serum bactericidal activity.
@nl
P2860
P1476
Naturally acquired passive pro ...... f serum bactericidal activity.
@en
P2093
Dan Granoff
Jo Anne Welsch
P2860
P304
P356
10.1128/IAI.72.10.5903-5909.2004
P407
P577
2004-10-01T00:00:00Z